SCHEMBL4298295

SCHEMBL4298295

COc1ccc(Cl)cc1S(=O)(=O)N[C@@H]1C[C@H](CN2C(=O)c3ccccc3C2=O)N(C(=O)O)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPT2 P23786 1/20 0.50
CPT1A P50416 1/20 0.50
CPT1B Q92523 1/20 0.50
BRD4 O60885 1/20 0.44
DRD2 P14416 4/20 0.42
ADRA1D P25100 4/20 0.42
ADRA1A P35348 4/20 0.42
ADRA1B P35368 4/20 0.42
RXFP1 Q9HBX9 1/20 0.41
ATM Q13315 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALPL P05186 2/20 0.40
NPC1 O15118 1/20 0.40
TSHR P16473 1/20 0.40
USP2 O75604 1/20 0.40
CTSL P07711 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4301872 0.91 CTSL (0.51) CPT2CPT1ACPT1BBRD4RXFP1
SCHEMBL8047069 0.90 CPT2 (0.46) CPT2CPT1ACPT1BBRD4DRD2
SCHEMBL4290246 0.90 BRD4 (0.44) CPT2CPT1ACPT1BBRD4DRD2
SCHEMBL3950906 0.89 ACLY (0.38) CPT2CPT1ACPT1BALDH1A1
SCHEMBL13662004 0.88 CPT2 (0.47) CPT2CPT1ACPT1BBRD4DRD2
SCHEMBL4294636 0.84 CPT2 (0.51) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL8063921 0.81 CTSL (0.48) BRD4DRD2ADRA1DADRA1AADRA1B
SCHEMBL4294665 0.81 CPT2 (0.53) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL8049539 0.81 BRD4 (0.44) CPT2CPT1ACPT1BBRD4ALDH1A1
SCHEMBL8063144 0.80 BRD4 (0.43) CPT2CPT1ACPT1BBRD4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE CTSB, CTSS, CTSF CPT2 3009/4885CPT1A 3354/4885CPT1B 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.